# Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

> **NCT01441973** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 41 (actual)

## Conditions studied

- Smoldering Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Elotuzumab (BMS-901608; HuLuc63)

## Key facts

- **NCT ID:** NCT01441973
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-28
- **Primary completion:** 2014-05-30
- **Final completion:** 2017-01-17
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2018-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01441973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01441973, "Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01441973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*